121
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

, ORCID Icon &
Pages 191-200 | Published online: 25 Nov 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (2)